Published On: Wed, Oct 19th, 2016

Latest Analyst Reports On Marinus Pharmaceuticals, Inc.


Recently stock market analysts have updated their consensus ratings on shares of Marinus Pharmaceuticals, Inc. (MRNS).

Most recent broker ratings

09/30/2016 – Marinus Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 3 price target on the stock.

06/28/2016 – Marinus Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Stifel Nicolaus.

06/14/2016 – Marinus Pharmaceuticals, Inc. was downgraded to “perform” by analysts at Oppenheimer.

06/14/2016 – Marinus Pharmaceuticals, Inc. was downgraded to “sector perform” by analysts at RBC Capital. They now have a USD 2 price target on the stock.

05/18/2015 – Marinus Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Janney Montgomery Scott. They now have a USD 20 price target on the stock.

05/13/2015 – Marinus Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Zacks. They now have a USD 9 price target on the stock.

08/26/2014 – JMP Securities began new coverage on Marinus Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 14 price target on the stock.

Marinus Pharmaceuticals, Inc. has a 50 day moving average of 1.71 and a 200 day moving average of 2.99. The stock’s market capitalization is 27.12M, it has a 52-week low of 1.19 and a 52-week high of 9.08.

The share price of the company (MRNS) was up +1.46%, with a high of 1.43 during the day and the volume of Marinus Pharmaceuticals, Inc. shares traded was 242896.